⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

December 27, 2019Journal of Thoracic OncologyOpen Access

Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis

View Full Paper

Ask AI

Bookmark

Share

Abstract

Patients with EGFR T790M-positive NSCLC and radiologically detected LM obtained clinical benefit from osimertinib (80 mg qd).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ahn et al. (2019) studied this question.

synapsesocial.com/papers/69df1a033b0ba53fb37a14cf https://doi.org/10.1016/j.jtho.2019.12.113

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerCohort Study · 2011 · 348 citations
2Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trialHuman Clinical Trial · 2016 · 714 citations
3Leptomeningeal metastasisNarrative Review · 2010 · 192 citations
4AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung CancerEarly-Phase Clinical Trial · 2014 · 2,210 citations
5A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancerEarly-Phase Clinical Trial · 2015 · 101 citations